On Course: 2019 Annual Report

Late-Stage, Diversified, Clinical Pipeline

Each of our four clinical-stage drug candidates target distinct mechanisms critical to overcoming cancer progression and drug resistance:

  • ME-401, an oral PI3K delta inhibitor;
  • Voruciclib, an oral CDK inhibitor; and
  • ME-344, a mitochondrial inhibitor targeting the OXPHOS complex.
  • Pracinostat, an oral HDAC inhibitor;

ME-401

Oral P13K Delta Inhibitor

INDICATION COMBINATION CLINICAL PROOF OF CONCEPT MARKETING APPROVAL STUDY COMMERCIAL RIGHTS

Follicular Lymphoma

Relapsed/refractory

Monotherapy

Phase 2 Accelerated Approval Trial 1

Excluding Japan

B-Cell Malignancies

Relapsed/refractory

Monotherapy

Rituxan® (rituximab)

Zanubrutinib2

60%
60%

clinical collaboration

Voruciclib

CDK Inhibitor

INDICATION COMBINATION CLINICAL PROOF OF CONCEPT MARKETING APPROVAL STUDY COMMERCIAL RIGHTS

B-Cell Malignancies & AML

Relapsed/refractory

Venclexta® (venetoclax)3
60%

ME-344

Mitochondrial Inhibitor

INDICATION COMBINATION CLINICAL PROOF OF CONCEPT MARKETING APPROVAL STUDY COMMERCIAL RIGHTS

HER2-Breast Cancer

Treatment-naive, early stage

Avastin® (bevacizumab)4
60%

Pracinostat

HDAC Inhibitor

INDICATION COMBINATION CLINICAL PROOF OF CONCEPT MARKETING APPROVAL STUDY COMMERCIAL RIGHTS

Acute Myeloid Leukemia

Treatment-naive

Vidaza®
(azacitidine)
Phase 3 Pivotal Trial

Myelodysplastic Syndrome

Treatment-naive

Vidaza®
(azacitidine)
60%

1 Phase 2 study to support an accelerated approval marketing application with FDA

2 Study arm initiated under clinical collaboration with BeiGene, Ltd.

3 Evaluation in combination with venetoclax is subject to FDA approval

4 Investigator-initiated trial